White House Drug Pricing Report: FDA Should Make Biosimilar Standards Easy To Comply With, Prioritize Me-Too Drugs

A newly released Council of Economic Advisors report on drug pricing, which is expected to inform HHS' fiscal 2019 budget request, is angering both public health advocates and those favoring sweeping drug pricing reforms, given it suggests FDA can lower drug prices by speeding FDA approvals of brand drugs and making FDA's approval standards easy to comply with, all while making no mention of brand industry-opposed reforms, including those that have been floated by FDA Commissioner Scott Gottlieb, such as...